HU228928B1 - Phospholipid complexes of proanthocyanidin a2 as antiatherosclerotic agents - Google Patents
Phospholipid complexes of proanthocyanidin a2 as antiatherosclerotic agents Download PDFInfo
- Publication number
- HU228928B1 HU228928B1 HU0104665A HUP0104665A HU228928B1 HU 228928 B1 HU228928 B1 HU 228928B1 HU 0104665 A HU0104665 A HU 0104665A HU P0104665 A HUP0104665 A HU P0104665A HU 228928 B1 HU228928 B1 HU 228928B1
- Authority
- HU
- Hungary
- Prior art keywords
- proanthocyanidin
- phospholipid complexes
- antiatherosclerotic agents
- phospholipid
- complexes
- Prior art date
Links
- 150000003904 phospholipids Chemical class 0.000 title description 5
- NSEWTSAADLNHNH-TXZJYACMSA-N Proanthocyanidin A-2 Natural products C1([C@H]2OC3=C4[C@H]5C6=C(O)C=C(O)C=C6O[C@]([C@@H]5O)(OC4=CC(O)=C3C[C@@H]2O)C=2C=C(O)C(O)=CC=2)=CC=C(O)C(O)=C1 NSEWTSAADLNHNH-TXZJYACMSA-N 0.000 title description 3
- 229920002982 Procyanidin A2 Polymers 0.000 title description 3
- NSEWTSAADLNHNH-UHFFFAOYSA-N pavetannin A-2 Natural products OC1CC2=C(O)C=C3OC(C4O)(C=5C=C(O)C(O)=CC=5)OC5=CC(O)=CC(O)=C5C4C3=C2OC1C1=CC=C(O)C(O)=C1 NSEWTSAADLNHNH-UHFFFAOYSA-N 0.000 title description 3
- NSEWTSAADLNHNH-LSBOWGMISA-N proanthocyanidin A2 Chemical compound C1([C@H]2OC3=C4[C@H]5C6=C(O)C=C(O)C=C6O[C@]([C@@H]5O)(OC4=CC(O)=C3C[C@H]2O)C=2C=C(O)C(O)=CC=2)=CC=C(O)C(O)=C1 NSEWTSAADLNHNH-LSBOWGMISA-N 0.000 title description 3
- 230000000879 anti-atherosclerotic effect Effects 0.000 title 1
- 238000002360 preparation method Methods 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 239000000284 extract Substances 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
(57) Kivonat
A találmány a proantocianidin A2 vagy proantocianidin A2-ben dúsított extraktumok foszfolipid-komplexeire, illetve ilyen vegyületeket tartalmazó, atheroszklerózis, továbbá miokardiális és cerebrális infarktus profilaktikus vagy terápiás kezelésére alkalmas gyógyászati készítményekre vonatkozik. A találmány szerinti foszfolipid-komplexekhez foszfolipidként például lecitint, foszfatidilkolint, foszfatidiletanolamint vagy foszfatidilszerint használhatunk, a komplexekben a proantocianidin A2-nek a foszfolipidre vonatkoztatott tömegaránya 2:1 és 1:2 közötti.
* .......·$
4X4 4
X 4 Λ·
4 S 4 4 4 4’ *
44X4 χ 4«X4
4· 9 X 4X4 X
·<*.·> ' ,4.svaló ai valamint
aahs as
3A1M3JS~í
2as3aMW>
imno(7$-d]I1 s3jbenzodioxocln>3A«ck'42R~ >él ízolát
Á-210
xwsfdtn gni, martették. Á praaotoeianidin Á2 foszfoitpidekksi alkotott keverékeinek al· kahwzésa atherossferesis kezelésére ismert au US~A~564$37? számú
2-ΦΦ.*·Χ Φ ΦΦΦΧ Φ φ φ .φ *
Φ X Φ ΦΧΦ » *' φ φ ΧΦΦΦ Φ *φφ» φφ φ φφφ φ
hTOrkotet
-3♦ ί Λ * -X <ί· X * X * <· X Χ·>Χ « * * *.«♦«-* « Χ*ί· <
># » *·Χ* *
zssi;
i a betegség súlyosságéi :í készítmények előáölihatók az e célra a szak smkkel» szokásos hordozó» és/vagy egyéb kívánjuk megvív
Rrosrstooi;
ltjuk, majd szemesaméretre
ö lat δ-
Ιό a
s majd a fc fcfcfc fcfcfcfc Of fc fc fc * fc fcfc fcfcfc fcfc « fc fcfc fcfc fc fcfcfcfc fcfc fc fcfcfc fc
$ «
200 mg 118 mg mg mg **** .* 'φφ&'φ 4‘
X S* « * * « SS· 4 * * φ 4 ❖ Ψψ.’ί 4
4JÍ * ¥«\* * ^mzzó talkum mag né sl
mg
a mc •φφ
Φ φ φ «.** φ * φ φ &φφ* φ φ*φφ
ΦΧ Φ «φί* Φ
Claims (1)
- Szabadalmi igénypont1, Prganfoáam rtfeslkgim foszfeffeil ixat lipid fedőm főszítin ?á$J axek, ahol a mse felfeslkohrt a pro tömegaranya z:i és 1:2U.5» ígér rlntl alkalmazás, mg hatóanyagot 1 a gyógyászati készít· íszats imazas.zsaiat imaz.CSkXMW, CX% , 02 > ö
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT1998MI002732A IT1304183B1 (it) | 1998-12-18 | 1998-12-18 | Complessi di proantocianidina a2 con fosfolipidi come agentiantiaterosclerotici. |
| PCT/EP1999/009854 WO2000037062A2 (en) | 1998-12-18 | 1999-12-13 | Phospholipid complexes of proanthocyanidin a2 as antiatherosclerotic agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| HUP0104665A2 HUP0104665A2 (hu) | 2002-04-29 |
| HUP0104665A3 HUP0104665A3 (en) | 2003-01-28 |
| HU228928B1 true HU228928B1 (en) | 2013-06-28 |
Family
ID=11381268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0104665A HU228928B1 (en) | 1998-12-18 | 1999-12-13 | Phospholipid complexes of proanthocyanidin a2 as antiatherosclerotic agents |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6429202B1 (hu) |
| EP (1) | EP1140115B1 (hu) |
| JP (1) | JP4842436B2 (hu) |
| KR (1) | KR100694907B1 (hu) |
| CN (1) | CN1146429C (hu) |
| AT (1) | ATE238803T1 (hu) |
| AU (1) | AU763907B2 (hu) |
| CA (1) | CA2355776C (hu) |
| CZ (1) | CZ301495B6 (hu) |
| DE (1) | DE69907509T2 (hu) |
| DK (1) | DK1140115T3 (hu) |
| ES (1) | ES2197708T3 (hu) |
| HK (1) | HK1042430B (hu) |
| HU (1) | HU228928B1 (hu) |
| IL (2) | IL143751A0 (hu) |
| IT (1) | IT1304183B1 (hu) |
| NO (1) | NO328733B1 (hu) |
| PL (1) | PL197153B1 (hu) |
| PT (1) | PT1140115E (hu) |
| RU (1) | RU2248798C2 (hu) |
| SK (1) | SK284884B6 (hu) |
| WO (1) | WO2000037062A2 (hu) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8507018B2 (en) * | 1998-03-12 | 2013-08-13 | Mars, Incorporated | Products containing polyphenol(s) and L-arginine and methods of use thereof |
| EP1482920B2 (en) * | 2002-02-12 | 2011-07-20 | Hunza di Pistolesi Elvira & C. S.a.S. | Compositions containing n-acyl-phosphatidyl-ethanolamines and/or mixtures of n-acyl-ethanolamines with phosphatidic acids or lysophosphatidic acids |
| ITMI20020756A1 (it) * | 2002-04-09 | 2003-10-09 | Sinclair Pharma S R L | Composizioni farmaceutiche topiche per il trattamento delle dermatiti |
| GB0321996D0 (en) * | 2003-09-19 | 2003-10-22 | Novartis Nutrition Ag | Organic compounds |
| EP1713467B1 (en) * | 2004-01-28 | 2012-08-01 | Mars, Incorporated | Compositions and methods of use of a-type procyanidins |
| EP1837030A1 (en) | 2006-03-09 | 2007-09-26 | INDENA S.p.A. | Phospholipid complexes of curcumin having improved bioavailability |
| WO2009104556A1 (ja) * | 2008-02-19 | 2009-08-27 | 株式会社岐阜セラツク製造所 | 組成物 |
| IT1398624B1 (it) * | 2009-02-02 | 2013-03-08 | Dermogyn S R L | Uso cosmetico della proantocianidina a2 |
| RU2456674C1 (ru) * | 2011-05-31 | 2012-07-20 | Тагир Уралович Гафаров | Способ моделирования атрофического рубца кожи |
| CN102688501A (zh) * | 2012-06-20 | 2012-09-26 | 浙江萧山医院 | 原花青素b2磷脂复合物及其制备方法和用途 |
| CN103120798A (zh) * | 2013-01-10 | 2013-05-29 | 施冬云 | 一种具有抗氧化应激作用的磷脂复合物制备方法及其应用 |
| CN103467778B (zh) * | 2013-09-06 | 2015-09-30 | 天津大学 | 细菌纤维素/卵磷脂复合材料及制备和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4698360B1 (en) | 1985-04-09 | 1997-11-04 | D Investigations Pharmacologiq | Plant extract with a proanthocyanidins content as therapeutic agent having radical scavenger effect and use thereof |
| GB8518289D0 (en) * | 1985-07-19 | 1985-08-29 | Inverni Della Beffa Spa | Obtaining proanthocyanidine a2 |
| IT1201149B (it) * | 1987-01-14 | 1989-01-27 | Indena Spa | Complessi di bioflavonoidi con fosfolipidi,loro preparazione,uso e composizioni farmaceutici e cosmetiche |
| IT1201151B (it) * | 1987-01-14 | 1989-01-27 | Indena Spa | Complessi fosfolipidici con estratti da vitis vinifera,procedimento per la loro preparazione e composizioni che li cntengono |
| IT1265312B1 (it) * | 1993-12-21 | 1996-10-31 | Indena Spa | Formulazioni contenenti carotenoidi e procarotenoidi associati a polifenoli nella prevenzione dei danni da abnorme produzione di |
| US5648377A (en) | 1993-12-21 | 1997-07-15 | Indena S.P.A. | Formulations containing carotenoids an procarotenoids combined with polyphenols in the prevention of the damages due to an abnormal production of free radicals |
| IT1270999B (it) * | 1994-07-26 | 1997-05-26 | Indena Spa | Formulazioni a base di cumarine e loro uso in campo farmaceutico e cosmetico |
| FI955691A (fi) * | 1994-11-28 | 1996-05-29 | Suntory Ltd | Lipoproteiini(a):ta alentava aine, kolesterolia alentava aine ja näitä aineita sisältävät lääkkeet |
| IT1296920B1 (it) * | 1997-12-04 | 1999-08-03 | Indena Spa | Uso di complessi di estratti vitis vinifera con fosfolipidi come agenti anti-aterosclerotici |
| EP1210785B1 (de) | 1999-09-08 | 2005-11-23 | Siemens Aktiengesellschaft | Anordnung und verfahren für eine optische informationsübertragung |
-
1998
- 1998-12-18 IT IT1998MI002732A patent/IT1304183B1/it active
-
1999
- 1999-12-13 ES ES99966956T patent/ES2197708T3/es not_active Expired - Lifetime
- 1999-12-13 AT AT99966956T patent/ATE238803T1/de active
- 1999-12-13 US US09/857,804 patent/US6429202B1/en not_active Expired - Lifetime
- 1999-12-13 CN CNB998144460A patent/CN1146429C/zh not_active Expired - Fee Related
- 1999-12-13 RU RU2001116085/15A patent/RU2248798C2/ru not_active IP Right Cessation
- 1999-12-13 SK SK860-2001A patent/SK284884B6/sk not_active IP Right Cessation
- 1999-12-13 IL IL14375199A patent/IL143751A0/xx active IP Right Grant
- 1999-12-13 CA CA002355776A patent/CA2355776C/en not_active Expired - Fee Related
- 1999-12-13 KR KR1020017007374A patent/KR100694907B1/ko not_active IP Right Cessation
- 1999-12-13 DK DK99966956T patent/DK1140115T3/da active
- 1999-12-13 EP EP99966956A patent/EP1140115B1/en not_active Expired - Lifetime
- 1999-12-13 PL PL349534A patent/PL197153B1/pl unknown
- 1999-12-13 PT PT99966956T patent/PT1140115E/pt unknown
- 1999-12-13 DE DE69907509T patent/DE69907509T2/de not_active Expired - Lifetime
- 1999-12-13 CZ CZ20012134A patent/CZ301495B6/cs not_active IP Right Cessation
- 1999-12-13 HU HU0104665A patent/HU228928B1/hu not_active IP Right Cessation
- 1999-12-13 AU AU22830/00A patent/AU763907B2/en not_active Ceased
- 1999-12-13 WO PCT/EP1999/009854 patent/WO2000037062A2/en active IP Right Grant
- 1999-12-13 JP JP2000589173A patent/JP4842436B2/ja not_active Expired - Fee Related
-
2001
- 2001-06-13 IL IL143751A patent/IL143751A/en not_active IP Right Cessation
- 2001-06-14 NO NO20012944A patent/NO328733B1/no not_active IP Right Cessation
-
2002
- 2002-04-30 HK HK02103200.8A patent/HK1042430B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU228928B1 (en) | Phospholipid complexes of proanthocyanidin a2 as antiatherosclerotic agents | |
| US6063400A (en) | Targeted liposomal constructs for diagnostic and therapeutic uses | |
| CA1237670A (en) | Drug preparations of reduced toxicity | |
| Hempelmann | Hemozoin biocrystallization in Plasmodium falciparum and the antimalarial activity of crystallization inhibitors | |
| CA2315230C (en) | Anti-cryptococcal peptides | |
| Mason et al. | Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine | |
| US5866615A (en) | Formulations and methods of use of 2,2'-dithio-bis-ethane sulfonate | |
| CA1283050C (en) | Anthraquinone drug composition and method | |
| Damment et al. | Clinical pharmacokinetics of the phosphate binder lanthanum carbonate | |
| AU2013296651B2 (en) | Cochleates made with soy phosphatidylserine | |
| EP2399587A1 (en) | Liposome treatment of viral infections | |
| US9872834B2 (en) | Nanocarrier therapy for treating invasive tumors | |
| BG104075A (en) | Combined treatment including atorvastatin and an antihypertonic form | |
| DK2143429T3 (en) | Use of cilastatin for reducing the nephrotoxicity of various compounds | |
| US20030026850A1 (en) | N,N-dinitramide salts as solubilizing agents for biologically active agents | |
| CA2353593A1 (en) | Method of administering a compound to multi-drug resistant cells | |
| Dowdall et al. | Inhibition of high-affinity choline transport in peripheral cholinergic endings by presynaptic snake venom neurotoxins | |
| BR0212155A (pt) | Composição farmacêutica | |
| Salama et al. | The effect of ΔG on the transport and oral absorption of macromolecules | |
| Bhandari et al. | Toxicity studies of highly bioavailable isoniazid loaded solid lipid nanoparticles as per Organisation for Economic Co-operation and Development (OECD) guidelines | |
| RU2001116085A (ru) | Фосфолипидные комплексы проантоцианидина а2 в качестве антиатеросклеротических агентов | |
| Garrahan | Inhibitors of the Ca2+ pump | |
| Richter | Mitochondrial calcium transport | |
| CA2410595A1 (en) | Use of aloe-emodin in the treatment of neuroectodermal tumors | |
| GEP20043377B (en) | Pharmaceutical Complex |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of definitive patent protection due to non-payment of fees |